Protalix BioTherapeutics, Inc. (DE) (PLX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics First Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer of Lakeside Advisors Investor Relations for Protallix. Thank you. Please go ahead. Thank you, Operator, and welcome to the Protallix Biotherapeutics Q1 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Portalix, and Gilad Mamlach, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and corporate updates were issued this morning and are available now on the Portalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Bratalex's filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Thank you, Mike, and thank you, everyone, for joining our Q1 2026 financial results and business update call. I want to begin by highlighting two points that underscore the strength of our business today. First, during the quarter we received the $25 million milestone from Chiesi, following the European Commission approval of El Fabrio's every four weeks dosing regime. As a result, we ended the first quarter of this year with $51 million in cash, providing us with a strong balance sheet and su...